Advanced Therapy Medicinal Products Market Size & Share, by Product (CAR-T Therapy, Gene Therapy, Cell Therapy, Tissue Engineered Product); Disease (Oncology, Genetic Disorder, CNS, Dermatology); End-user (Hospitals & Clinics, Research & Academic Institutes) - Global Supply & Demand Analysis, Growth Forecasts, Statistics Report 2023-2031

  • Report ID: 4684
  • Published Date: Feb 14, 2023
  • Report Format: PDF, PPT
  1. Introduction
    1. Market Definition
    2. Market Segmentation
    3. Product Overview
  2. Assumptions and Acronyms
  3. Research Methodology
    1. Research Process
    2. Primary Research
      1. Manufacturers
      2. Distributors
      3. End Users
    3. Secondary Research
    4. Market Size Estimation
  4. Executive Summary – Global Advanced Therapy Medicinal Products Market
  5. Analysis of Market Dynamics
    1. Drivers
    2. Trends
  6. Key Market Opportunities for Business Growth
  7. Major Roadblocks for the Market Growth
  8. Regulatory & Standard Landscape
  9. Value Chain Analysis
  10. Potential ATMP Treatment Analysis
  11. Pricing Analysis of Global Advanced Therapy Medicinal Products Market
  12. Use Case Analysis
  13. Pipeline Analysis
  14. Analysis on the Manufacturing Process
  15. Analysis of COVID-19 Impact on the Global Advanced Therapy Medicinal Products Market
  16. Analysis of End-User Market Share of Global Advanced Therapy Medicinal Products
  17. Competitive Positioning
  18. Competitive Landscape
    1. Market Share Analysis of Major Players (%), 2021
    2. Competitive Benchmarking
      1. Novartis AG.
      2. Takeda Pharmaceutical Company Limited
      3. Gilead Sciences, Inc.
      4. Bluebird Bio, Inc
      5. BioMarin Pharmaceutical Inc
      6. Vericel Corporation
      7. Mallinckrodt Pharmaceuticals
      8. UniQure N.V.
      9. JCR Pharmaceuticals Co., Ltd.
      10. Spark Therapeutics, Inc. (Parent Company: Roche)
      11. Kolon TissueGene, Inc. 
  19. Global Advanced Therapy Medicinal Products Market Outlook
    1. By Value (USD million)
    2. By Product
      1. CAR-T Therapy, 2023-2033F (USD million)
      2. Gene Therapy, 2023-2033F (USD million)
      3. Cell Therapy, 2023-2033F (USD million)
      4. Tissue Engineered Product, 2023-2033F (USD million)
    3. By Disease
      1. Oncology, 2023-2033F (USD million)
      2. Genetic Disorders, 2023-2033F (USD million)
      3. CNS, 2023-2033F (USD million)
      4. Dermatology, 2023-2033F (USD million)
      5. Others, 2023-2033F (USD million)
    4. By End-User
      1. Hospitals & Clinics, 2023-2033F (USD million)
      2. Research & Academic Institutes, 2023-2033F (USD million)
    5. Global Advanced Therapy Medicinal Products Market by Region
      1. North America, 2023-2033F (USD million)
      2. Europe, 2023-2033F (USD million)
      3. Asia-Pacific, 2023-2033F (USD million)
      4. Latin America, 2023-2033F (USD million)
      5. Middle East & Africa, 2023-2033F (USD million)
  20. North America Advanced Therapy Medicinal Products Market Outlook
    1. By Value (USD million)
    2. By Product
      1. CAR-T Therapy, 2023-2033F (USD million
      2. Gene Therapy, 2023-2033F (USD million)
      3. Cell Therapy, 2023-2033F (USD million)
      4. Tissue Engineered Product, 2023-2033F (USD million)
    3. By Disease
      1. Oncology, 2023-2033F (USD million)
      2. Genetic Disorders, 2023-2033F (USD million)
      3. CNS, 2023-2033F (USD million)
      4. Dermatology, 2023-2033F (USD million)
      5. Others, 2023-2033F (USD million)
    4. By End-User
      1. Hospitals & Clinics, 2023-2033F (USD million)
      2. Research & Academic Institutes, 2023-2033F (USD million)
    5. By Country
      1. US, 2023-2033F (USD million)
      2. Canada, 2023-2033F (USD million)
  21. Europe Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. UK, 2023-2033F (USD Million)
      2. Germany, 2023-2033F (USD Million)
      3. France, 2023-2033F (USD Million)
      4. Italy, 2023-2033F (USD Million)
      5. Spain, 2023-2033F (USD Million)
      6. Russia, 2023-2033F (USD Million)
      7. Netherlands, 2023-2033F (USD Million)
      8. Rest of Europe, 2023-2033F (USD Million)
  22. Asia Pacific Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. China, 2023-2033F (USD Million)
      2. India, 2023-2033F (USD Million)
      3. Japan, 2023-2033F (USD Million)
      4. South Korea, 2023-2033F (USD Million)
      5. Singapore, 2023-2033F (USD Million)
      6. Australia, 2023-2033F (USD Million)
      7. Rest of Asia-Pacific, 2023-2033F (USD Million)
  23. Latin America Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. Brazil, 2023-2033F (USD Million)
      2. Argentina, 2023-2033F (USD Million)
      3. Mexico, 2023-2033F (USD Million)
      4. Rest of Latin America, 2023-2033F (USD Million)
  24. Middle East & Africa Advanced Therapy Medicinal Products Market Outlook
    1. By Product
    2. By Disease
    3. By End User
    4. By Country
      1. GCC, 2023-2033F (USD Million)
      2. Israel, 2023-2033F (USD Million)
      3. South Africa, 2023-2033F (USD Million)
      4. Rest of Middle East & Africa, 2023-2033F (USD Million)

Global Market Size, Forecast, and Trend Highlights Over 2023-2031

Advanced Therapy Medicinal Products Market size is anticipated to cross USD 31,706.8 Million by the end of 2031, growing at a CAGR of 13.4% during the forecast period, i.e., 2021-2031. In the year 2021, the industry size of  advanced therapy medicinal products was USD 9,097.5 Million. The growth of the market can be attributed to the increased prevalence of the genetic disorder. Drugs used in gene therapy are advanced therapy medicinal products that contain genes that have therapeutic, preventative, or diagnostic effects. Recombinant genes are inserted into the body to cure a number of illnesses, such as cancer, genetic problems, and chronic diseases. For instance, all over the world around 300 million people are living with a rare disease and it affects nearly 4% to 6% of the total world population.

In addition to these, factors that are believed to fuel the growth of the advanced therapy medicinal products market include higher adoption of gene therapy. Gene therapy is known to be one of the advanced therapy medicinal products. The therapy is used to treat the underlying genetic disorder by correcting the faulty gene in the body.  In one study, 93 percent of respondents supported the use of gene therapy to treat Leber congenital amaurosis, an inherited form of blindness, while just 35 percent said it was certainly okay to use it to improve memory. Furthermore, advanced therapy medicinal products are used to replace or restore dopamine transmission in various parts of the nervous system. Therefore, increased cases of neurological ailment are anticipated the higher projection of the advanced therapy medicinal products market.  According to the Pan American Health Organization’s 2019 statistics, around 7.5 million people are living with a neurological disorder and 533,172 deaths are due to the neurological condition.


Advanced-Therapy-Medicinal-Products-Market-scope
Get more information on this report: Request Free Sample PDF


Advanced Therapy Medicinal Products Market: Key Insights

Base Year

2021

Forecast Year

2021-2031

CAGR

13.4%

Base Year Market Size (2021)

USD 9,097.5 Million

Forecast Year Market Size (2031)

USD 31,706.8 Million

Regional Scope

  • North America (U.S., and Canada)
  • Latin America (Mexico, Argentina, Rest of Latin America)
  • Asia-Pacific (Japan, China, India, Indonesia, Malaysia, Australia, Rest of Asia-Pacific)
  • Europe (U.K., Germany, France, Italy, Spain, Russia, NORDIC, Rest of Europe)
  • Middle East and Africa (Israel, GCC North Africa, South Africa, Rest of the Middle East and Africa)
Get more information on this report: Request Free Sample PDF

Advanced Therapy Medicinal Products Sector: Growth Drivers and Challenges

Market-Growth-Drivers

Growth Drivers

  • Rising Problems of Genetic Diseases

An illness characterized by one or more anomalies in the genome is referred to as a genetic condition. Advanced therapy medicinal products are one of the most effective ways to treat genetic disorder. According to the World Health Organization, around 2%–5% of all live births are affected by genetic illnesses and congenital anomalies, which can also be responsible for up to 50% of infant fatalities and 30% of pediatric hospital admissions in developed nations.

  • Increase in Neurological Disorders

Neurological disorder has become more prevalent among the people. People are getting affected by dementia, Alzheimer’s disease and others. As per the statistics of the United Nations, every year around 6.8 million people die of maladies, moreover, every 1 in 6th person is suffering from a neurological disorder.

  • Higher Demand for Gene Therapy

Gene therapy is used to replace the faulty gene and add the fit gene to the body. this procedure helps in fighting various diseases, such as cancer, AIDS, diabetes, and others. The number of people to be treated by gene therapy is estimated to be around 1 million from the year 2020 to 2034.

  • Growing Investment in Advanced Therapy Medicinal Products

With the increase in investment in the market, the research and development of advanced therapy medicinal products are also rising. In 202o, around USD 360 million were invested in cell therapy alone, and by 2021 it grew to nearly USD 70 billion.

  • Rise in the Development of New and Better Solutions

By the reports of the World Economic Forum, currently, there are more than 2000 advanced therapies in the development stage, and they are expected to treat larger pool of diseases.

Challenges

  • Advanced therapy medicinal products are not cost-effective- Advanced therapy medicinal products are typically highly customized or catered to a certain group of patients. As a result, it is challenging to automate or conform to good manufacturing standards in their manufacturing to achieve commercialization at an affordable level. Therefore, the high cost of the products is to hamper the market growth.
  • Restrictions for biopharmaceutical businesses to produce these treatments
  • Improper reimbursement assessment in medical products for advanced therapy


Advanced Therapy Medicinal Products Segmentation

Disease (Oncology, Genetic Disorder, CNS, Dermatology)

The global advanced therapy medicinal products market is segmented and analyzed for demand and supply by disease into oncology, genetic disorder, CNS, dermatology, and others. Out of all, the dermatology segment is to garner the highest revenue of USD 9,498 million at the end of 2031, by growing at a CAGR of 12.5% over the forecast period. Moreover, in 2020, the segment garnered a revenue of USD 2,961.7 million. The segment growth is expected on the back of rising cases of skin problems and cancer in the world. According to the World Health Organization, currently, 132,000 cases of melanoma and 2 to 3 million cases of non-melanoma skin cancer are reported annually worldwide. Skin cancer accounts for one in three cancer diagnoses, and one in five Americans will have it at some point in their lives.

Product (CAR-T Therapy, Gene Therapy, Cell Therapy, Tissue Engineered Product)

The global advanced therapy medicinal products market is also segmented and analyzed for demand and supply by product into CAR-T therapy, gene therapy, cell therapy, and tissue-engineered product. Amongst these four segments, the gene therapy segment is expected to garner a market revenue of USD 11,674.9 million at the end of 2031 by growing at a CAGR of 13.8% over the forecast period. Moreover, the segment generated a revenue of USD 3,241.9 million in 2021. The segment growth is expected on the back of a higher number of people in need of gene therapy and growing clinical trials of gene therapy. By 2034, gene therapies could be used to treat more than 1 million Americans. Furthermore, in 2022, around 1221 cell and gene therapies are under active clinical trials, moreover, out of them nearly 324 clinical trials are in the phase of 1/1b.

Our in-depth analysis of the global market includes the following segments:

          By Product

  • CAR-T Therapy
  • Gene Therapy
  • Cell Therapy
  • Tissue Engineered Product

               By Disease

  • Oncology
  • Genetic Disorder
  • CNS
  • Dermatology
  • Others

                By End User

  • Hospitals & Clinics
  • Research & Academic Institutes

Want to customize this research report as per your requirements? Our research team will cover the information you require to help you take effective business decisions.

Customize this Report

Advanced Therapy Medicinal Products Industry - Regional Synopsis

North American Market Forecast   

The North America advanced therapy medicinal products market, amongst the market in all the other regions, is projected to hold the largest market share of USD 14,020.7 million by the end of 2031 by growing at a CAGR of 13.1% over the forecast period. The region generated the revenue of USD 4,150.3 million in 2021. The market growth in North America is attributed to higher cases of cancer and neurological disorder followed by investment by private companies for the development of advanced therapy medicinal products. In 2022, around 600,000 deaths are attributed to the cancer cases and nearly 2 million new cases of cancer were diagnosed in the United States. Furthermore, in 2019, Pfizer Inc. a leading U.S. based pharmaceutical company announced the investment of USD 500 million to expand the gene therapy manufacturing unit in Sanford, North Carolina.

Research Nester
Advanced-Therapy-Medicinal-Products-Market-Share
Get more information on this report: Request Free Sample PDF

Companies Dominating the Advanced Therapy Medicinal Products Landscape

top-features-companies
    • Novartis AG
      • Company Overview
      • Business Strategy
      • Key Product Offerings
      • Financial Performance
      • Key Performance Indicators
      • Risk Analysis
      • Recent Development
      • Regional Presence
      • SWOT Analysis
    • Takeda Pharmaceutical Company Limited
    • Gilead Sciences, Inc.
    • Bluebird Bio, Inc.
    • BioMarin Pharmaceuticals Inc.
    • Vericel Corporation
    • Mallinckrodt Pharmaceuticals
    • UniQure N.V.
    • JCR Pharmaceuticals Co., Ltd.
    • Spark Therapeutics, Inc.
    • Kolon TissueGene,Inc.

In-the-news

In The News

  • Novartis AG in collaboration with Medicines for Malaria Venture announced the entry of novel ganaplacide/lumenfantrine-SDF into the phase 3 study. This novel is a combination to treat uncomplicated malaria in both adults and children.

  • Takeda Pharmaceutical Company Limited announced the collaboration and licensing agreement with Zedira and Dr.Falk Pharma for the development of first in class Celiac disease therapy. It is a serious autoimmune disease, in which intake of gluten damages the small intestine.


Author Credits:  Radhika Gupta, Shivam Bhutani


  • Report ID: 4684
  • Published Date: Feb 14, 2023
  • Report Format: PDF, PPT

Frequently Asked Questions (FAQ)

Rising instances of gene mutation and neurological condition, increased investment in the research and development of advance therapy medicinal products and higher demand of gene therapy are few factors which are likely to augment the market growth.

The market is anticipated to attain a CAGR of 13.4% over the forecast period, i.e., 2021-2031.

The market is likely to be hampered by high cost of treatment, strict regulation on the manufacturers for its production and poor assessment of reimbursement policy.

The market in North America is projected to hold the largest market share USD 14,020.7 million by the end of 2031 by growing at a CAGR of 13.1% over the forecast period. The region generated the revenue of USD 4,150.3 million in 2021 and provide more business opportunities in the future.

The major players in the market are Novartis AG, Takeda Pharmaceutical Company Limited, Gilead Sciences, Inc., Bluebird Bio, Inc., BioMarin Pharmaceuticals Inc., Vericel Corporation, Mallinckrodt Pharmaceuticals, UniQure N.V., JCR Pharmaceuticals Co., Ltd., Spark Therapeutics, Inc., Kolon TissueGene,Inc., and others.

The company profiles are selected based on the revenues generated from the product segment, geographical presence of the company which determine the revenue generating capacity as well as the new products being launched into the market by the company.

The market is segmented by product, disease, end user, and by region.

The dermatology segment is anticipated to garner the largest market size of USD 9,498 million at the end of 2031, by growing at a CAGR of 12.5% over the forecast period. Moreover, in 2020, the segment garnered a revenue of USD 2,961.7 million and display significant growth opportunities.
Advanced Therapy Medicinal Products Market Report Scope
  GET A FREE SAMPLE

FREE Sample Copy includes market overview, growth trends, statistical charts & tables, forecast estimates, and much more.

 Request Free Sample Copy

Have questions before ordering this report?

Inquiry Before Buying